​What is the best peptide to help reduce visceral fat

When it comes to reducing visceral fat, the peptide with the strongest clinical backing is Tesamorelin.

Here is why it stands out:

​

• Mechanism: Tesamorelin is a synthetic analog of Growth Hormone–Releasing Hormone (GHRH). It stimulates your pituitary gland to release more natural growth hormone, which in turn increases IGF-1. This cascade helps mobilize stored fat, particularly in the visceral (abdominal) area.

​

• Evidence: It has FDA approval for reducing visceral adipose tissue in HIV-associated lipodystrophy, but studies have also shown benefits in non-HIV populations dealing with central obesity.

​

• Results: Clinical trials show reductions in visceral fat while preserving lean muscle mass, which is often a challenge when dieting.

​

• Other benefits: It may improve lipid profiles, insulin sensitivity, and markers of metabolic health, though results vary between individuals.​

​

Other peptides sometimes discussed for fat loss (like CJC-1295/Ipamorelin or AOD-9604) may support overall body composition, but none are as well-documented for specifically targeting visceral fat as Tesamorelin.

​

Breakdown of Tesamorelin protocols and dosing strategies used for visceral fat reduction, based on clinical and anecdotal sources:

 

1. Standard Clinical Dose

• Dose: 2 mg subcutaneously once daily

• Frequency: Every day, usually in the evening

• Duration: Typically 3 months to see significant reduction in visceral fat; some protocols extend up to 6 months for continued improvement

• Monitoring: Periodic measurement of visceral fat via imaging (CT or MRI) or waist circumference, along with IGF-1 levels to ensure physiological range

 

2. Administration Tips

• Injection site: Rotate subcutaneous sites (abdomen, thighs, upper arm) to minimize irritation

• Timing: Evening injections are recommended because natural growth hormone release is higher at night, which may enhance synergy

• Lifestyle synergy: Combining Tesamorelin with resistance training and a high-protein, moderate-calorie diet amplifies fat loss while preserving lean mass

 

3. Expected Results

• Clinical trials show 8–15% reduction in visceral fat after 3 months

• Subcutaneous fat (the fat under the skin) is less affected

• Lean body mass is generally preserved, which is a key advantage over calorie-restricted dieting alone

 

4. Safety Considerations

• Generally well-tolerated, but possible side effects include:

• Mild injection site reactions

• Joint stiffness or swelling

• Temporary glucose intolerance in some cases

• People with active cancer, pituitary disorders, or uncontrolled diabetes should avoid it unless supervised by a physician

 

5. Alternatives / Adjuncts

• CJC-1295 + Ipamorelin: May improve growth hormone pulsatility and support lean mass, but visceral fat reduction is less pronounced than Tesamorelin

• AOD-9604: Mild lipolytic effect; mostly subcutaneous fat, minimal visceral impact